Castellano | Euskara | Français | English
DAR No 9. Dutasteride/Tamsulosin (Duodart®) in hiperplasia benign prostatic hyperplasia
Share it
Why associate?
- The combination dutasteride/tamsulosin is indicated in the management of moderate to severe symptoms of BPH and in the reduction of the risk of acute urinary retention and surgery in these patients.
- In the only published study, the combination did not clearly demonstrate the superiority of the combination when compared to dutasteride in monotherapy with regard to the reduction of acute urinary retention or the need for surgery.
- Adverse reactions were more frequent in the group under combined therapy compared to monotherapy, and no differences were seen with regard to treatment withdrawal due to adverse effects in either group. The incidence of heart failure was higher in patients treated with tamsulosin alone or combined while the incidence of ejaculation disorders and erectile dysfunction was higher in patients who were treated with dutasteride either alone or in combination.
